	US 12,427,170 B2
	Universal donor cells
Alireza Rezania, Cambridge, MA (US); and Rebeca Ramos-Zayas, Cambridge, MA (US)
Assigned to CRISPR THERAPEUTICS AG, Zug (CH)
Filed by CRISPR THERAPEUTICS AG, Zug (CH)
Filed on Aug. 9, 2022, as Appl. No. 17/818,669.
Application 17/818,669 is a continuation of application No. 17/383,760, filed on Jul. 23, 2021, granted, now 11,433,103.
Application 17/383,760 is a continuation of application No. 17/013,135, filed on Sep. 4, 2020, granted, now 11,116,797, issued on Sep. 14, 2021.
Claims priority of provisional application 62/979,756, filed on Feb. 21, 2020.
Claims priority of provisional application 62/896,477, filed on Sep. 5, 2019.
Prior Publication US 2023/0070540 A1, Mar. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/74 (2006.01); A61K 35/39 (2015.01); C12N 5/071 (2010.01); C12N 5/0735 (2010.01); C12N 5/074 (2010.01); C12N 5/10 (2006.01); C12N 5/16 (2006.01)

CPC A61K 35/39 (2013.01) [C07K 14/70539 (2013.01); C12N 5/0606 (2013.01); C12N 5/0607 (2013.01); C12N 5/0678 (2013.01); C12N 5/0696 (2013.01); C12N 5/10 (2013.01); C12N 5/16 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01)]

29 Claims

1. A genetically modified cell comprising (a) a nucleotide sequence encoding programmed death-ligand 1 (PD-L1) inserted within a gene encoding beta-2 microglobulin (B2M) and (b) a nucleotide sequence encoding HLA class I histocompatibility antigen, alpha chain E (HLA-E) inserted within a gene encoding thioredoxin interacting protein (TXNIP), wherein the genetically modified cell expresses PD-L1 and HLA-E and does not express B2M and TXNIP.